Advancing Molecular Glue Discovery with High-Throughput Spectral Shift Technology

Across the biopharmaceutical landscape, interest in molecular glues continues to grow. These small molecules work by stabilizing interactions between a target protein and an E3 ligase, enabling selective protein degradation. This mechanism offers a promising strategy for modulating disease-relevant proteins in ways that are not achievable with traditional inhibition approaches. Within integrated drug discovery programs, molecular glues are increasingly viewed as valuable additions to Medicinal Chemistry toolbox, particularly for targets considered difficult or undruggable.

Recent work from Eurofins Discovery highlights how innovative biophysical screening methods can accelerate this field by enabling direct, high-throughput identification of molecular glue candidates.

A New High-Throughput Biophysical Approach

In this work, we present a fluorescence‑based Spectral Shift technology specifically adapted for ultra‑high‑throughput screening in 1536‑well plates. The approach starts with freshly labeling the target protein with a fluorescent dye, ensuring optimal signal quality for each experiment. When a ligand binds to the protein, it induces subtle but measurable changes in the dye’s emission spectrum.

By monitoring shifts in fluorescence intensity between 650 nm and 670 nm, binding events can be detected in real time. Compounds that interact with the target produce either positive or negative spectral shifts, allowing rapid and reliable hit identification across large chemical libraries. Beyond simple hit finding, the assay also supports quantitative analysis: dose–response experiments generate clean sigmoidal curves from which dissociation constants (KD) can be derived.

Together, this setup combines speed, sensitivity, and quantitative precision, making it a powerful platform for early discovery screening and affinity characterization within Medicinal Chemistry driven discovery workflows.

Identifying a WEE1 Molecular Glue Degrader

Leveraging the Spectral Shift screening platform, Eurofins Discovery successfully identified a molecular glue degrader that promotes interaction between the kinase WEE1 and the E3 ligase cereblon (CRBN). The campaign was carried out using purified recombinant proteins and a focused compound library, all formatted for ultra‑high‑throughput screening in 1536‑well plates.

A key advantage of the technology is its ability to directly detect ternary complex formation, capturing the simultaneous interaction between WEE1, CRBN, and small‑molecule candidates. This direct biophysical readout enabled rapid prioritization of compounds with the desired molecular glue behavior.

Following initial identification, the lead compound was rigorously characterized using a suite of orthogonal assays, spanning target‑based, biophysical, and cellular platforms. Cellular activity was further confirmed by assessing WEE1 degradation through Western blot analysis and quantitative proteomics, providing strong validation of the compound’s mechanism of action.

Accelerating the Path to Targeted Protein Degraders

For scientists working in Medicinal Chemistry and targeted protein degradation and induced proximity mechanisms, Spectral Shift technology provides a powerful and accessible entry point into molecular glue discovery. Designed for scalability, this approach enables rapid, high‑throughput screening of compound libraries while delivering rich spectral readouts that support early and detailed binding characterization.

By integrating biophysical insight at the front end of the discovery workflow, Spectral Shift technology helps research teams make informed decisions sooner. When complemented by orthogonal profiling platforms, it streamlines compound triage, reduces attrition, and accelerates progression from initial hypotheses to validated degrader candidates, ultimately supporting a more efficient and confident discovery journey.

Looking Ahead

Combining high‑throughput, biophysics‑driven screening with downstream cellular and proteomic analyses establishes a robust framework for expanding the molecular glue landscape. This integrated platform is poised to unlock new opportunities in targeted protein degradation by enabling reliable, efficient identification of functional degraders, paving the way for innovative therapeutic programs and next‑generation drug discovery efforts.

Contact our experts now, if you want to take a deep dive in our Integrated Chemistry solutions: https://apac.eurofinsdiscovery.com/usermanagement/customer-services